Thank you for the submission of your manuscript to EMBO Molecular Medicine. We have now heard back from the three Reviewers whom we asked to evaluate your manuscript.
As you know, EMBO Molecular Medicine has a "scooping protection" policy, whereby similar findings that are published by others during review or revision are not a criterion for rejection. However, I do ask you to get in touch with us after three months if you have not completed your revision, to update us on the status. Please also contact us as soon as possible if similar work is published elsewhere.
Last, but not least important and as mentioned above, please note that EMBO Molecular Medicine now requires a complete author checklist (http://embomolmed.embopress.org/authorguide#editorial3) to be submitted with all revised manuscripts (also attached to this letter).
I look forward to seeing a revised form of your manuscript as soon as possible. ***** Reviewer's comments ***** Referee #1 (Comments on Novelty/Model System):
There is no doubt that the area of PD-1 modulation of anti-tumor immunity is currently of intense and highly competitive interest with respect to translational immunology impacts. This paper offers some new insights and may possibly offer some new therapeutic targets. The reliance on the slightly 'easy win' of the B16 melanoma model possibly diminishes slightly ones enthusiasm for adequacy of the model system Referee #1 (Remarks):
In this manuscript by Li and colleagues a number of substantive new insights are offered about the role of the SKAP-55/ADAP pathway in modulation of PD-1 expression and thus, the potential for modulatory effects on tumor killing. The points are novel and in many respects, well evidenced by the data.
The Abstract could be considerably sharpened. The wording was sometimes ambiguous. For example, in line 5 where it is stated that "KO mice profoundly prevented tumor formation", this needs to be rephrased as something like "knockout of SKAP 55 or ADAP in mice was associated with protection from tumor metastases". In Abstract, line 6: the use of the term "related to" seemed an evasive why to describe a functional relationship. The final part of the Abstract re patients who have severe adverse effects against PD-1 mAbs seemed out of step with the actual contents or implications of the study (-possibly an OTT effort to market the work to a translational audience?) p3. line 5, typo: "has been shown" Unclear here precisely what the authors mean by the term "clinical anti-tumour activity" p3 para 2, line 3. The authors seem to imply that PD-1 effects have been limited to the tumor immunity field, which obviously is not the case p5, para 3, typo " also showed decreased PD-1" p6 para 1, line 2, typo "after being treated"
In Figure 1F labeling, the legend and text clarify that this shows over-expression rather than knockout, but this is not clear from looking at labeling of the figure itself. Also, I may have missed this, could not see data on the extent of over-expression after transfection?
The point about the phenotype of the knockouts is on the whole well made, but I was disappointed not to see any data from the double knockouts. What phenotype does this give? p6, para 3, line 13: Would be more clearly rephrased along the lines of " Taken together, this offers the first data in support of....." I would have found the tumor protection data more persuasive if some of the information from FigS4B was shown in the main paper and more extensively described. That is, we need to see number about numbers of metasteses, not just 'survival'. It would also be good to see more comprehensive analysis of T effector infiltrates.
One might have perhaps wished for a wider consideration of some more challenging tumor models in these studies, but, nevertheless, some very interesting findings.
Referee #2 (Comments on Novelty/Model System):
There is an ethical concern. In the paragraph: "SKAP55 deficient mice enhance DC-based vaccine for prevention of tumors in vivo", the authors analyse the ability of DC-based vaccination to prevent tumor growth in SKAp55-/-mice. Survival rates and tumor multiplicity are shown. Current Ethical Guideline recommends choosing endpoints that minimize pain and/or distress to the animals. The observation of the tumor multiplicity in the lung is an endpoint sufficient to assess the preventive anti-tumor efficacy of the vaccine and is a much more humane endpoint than survival. Survival curves should not be shown.
Referee #2 (Remarks):
The authors investigate the mechanisms underlying the expression of programmed death-1 (PD-1) during anti-tumor immunotherapy. The results show that the deficiency of ADAP or SKAP55 inhibits PD-1 expression and enhances the anti-tumor effectiveness of immunotherapy.
General comments: Antibodies that block novel checkpoint molecules, including PD-1 and PD-L1, have demonstrated activity in multiple tumour types, in clinical and pre-clinical studies, therefore the study of the control of PD-1 expression is highly relevant for cancer research. On the whole, the data are very innovative and the results presented are very convincing. Nevertheless, the conclusions drawn are far away from the realistic conclusions suggested by the results. It would be advisable to rewrite the discussion more in the light of a mechanistic study rather than as if the authors had discovered a new way of targeting PD-1.
Specific observations: 1. The manuscript should be carefully revised for the English. 2. There is an ethical concern. In the paragraph: "SKAP55 deficient mice enhance DC-based vaccine for prevention of tumors in vivo", the authors analyse the ability of DC-based vaccination to prevent tumor growth in SKAp55-/-mice. Survival rates and tumor multiplicity are shown. Current Ethical Guideline recommends choosing endpoints that minimize pain and/or distress to the animals. The observation of the tumor multiplicity in the lung is an endpoint sufficient to assess the preventive anti-tumor efficacy of the vaccine and is a much more humane endpoint than survival. Survival curves should not be shown. 3. There is also a major concern about the statistical analysis. Statistical significance was determined with two-tailed Student's t-test, the use of a non-parametric statistical test is strongly recommended. 4. In the discussion, the authors suggest a new usage of Cyclosporine A for tumour therapy. Nevertheless, in the present study only in vitro studies were done to support this hypothesis and concerns are raised by the fact that Cyclosporine A is a powerful immunosuppressant drug. It would be more appropriate to make this statement more cautious in view of the frequent observation of increased incidence of different types of tumors in individuals treated with cyclosporine.
Referee #3 (Comments on Novelty/Model System):
The high importance is given by the fact that anti-PD-1 is currently a novel and successful immunetherapy in cancer and by the clear effects seen in the authors mouse model system. In my mind impact could be higher if they compare their results with the effect of CSA (see comments to authors. If CSA indeed down-regulates PD-1 in vivo it would certainly be of broad interest.
Referee #3 (Remarks):
In their manuscript Li and coworkers describe that PD-1 is upregulated on CD8 CTL when they are deficient of the ADAP-SKAP55 signaling module. This mechanism has implications for translational medicine as current cancer immunotherapy schemes use anti-PD-1 antibodies successfully to increase the effector-functions of anti-tumor CTL. At least in DC vaccine mouse model they demonstrate, that CTL deficient of ADAP-SKP55 have much higher tumor clearance potency than WT cells. Therefore the authors argue that this signaling module should be targeted for therapeutic reasons. This is a well written manuscript on a timely subject which has the necessary mix of in vitro analyses, system manipulation and animal model data as well as the necessary technical quality. I have only a few comments. 1) The authors suggest that the ADAP-SKAP55 module should be targeted when/as side effects of anti-PD-1 treatment are severe. Usually this targeting would likely produce a drug which itself may have severe side effects unless the authors think of CSA which, in their assay systems, has a significant effect on PD-1 expression ( figure 3D ). Unfortunately they do not demonstrate statistical significance, although it looks like being significant, and they have not used CSA in their DCvaccine mouse model system. Judging from the in vitro data, it would be interesting to compare the CSA effect with ADAP-SKAP55 deficiency. If the effect would be comparable, as could be expected from the in vitro data, this would be an important notion for the field and their study and CSA could be tested as a "poor man's" anti-PD-1 drug. In this case, the CSA effect should be included into the abstract and the keywords. 2) Without the proper controls (specific/nonspecific competitor probe) an EMSA as in figure 3C is not very meaningful and should be repeated. The indicated band could be nonspecific. We thank the Editors and reviewers for providing constructive suggestions. We are glad that all reviewers thought our work is interesting and of potential importance. We also carefully considered their comments and performed substantially experiments. Please find the point-by-point responses to the Editors and reviewers' comments. The changes in the text and figures are labeled with red colour. Editors' comments Reviewer 1, S/he would like to see the data on the extent of over-expression of SKAP55 and on the double knock-outs. Finally, Reviewer 1 also suggests that the figure illustrating the data on tumour protection be made a main one and mentions that survival, as opposed to the numbers of metastases is not a good indicator. Fig. S1C ) and the double KOs (Fig. 2F, Supplementary Fig. S2D, S3B, S6C) . We also removed the survival curve from the revised manuscript.
We have followed the reviewer's suggestion and added new data about SKAP55 overexpression (Supplementary
Reviewer 2 similarly to Reviewer 1, suggests careful revision for English usage. … First, s/he suggests that the statistical analysis of your results should be redone with a better-suited approach. ... The other concern raised by Reviewer 2 is an ethical one with respect to animal experimentation;… In this respect the request by Reviewer 1 to provide better lung tumour data is especially fitting. I must also ask you to provide more details in the Materials and Methods section identifying the institutional and/orlicensing committee approving the experiments, also including any relevant details (like how many animals were used, of which gender, at what age, which strains, if genetically modified, on which background, housing details, etc). …Connected to this and the above-mentioned statistics issue, we are now requesting all Authors to complete an Author checklist (see below). .. Fig. 4A and Supplementary Fig. S5 .
We have asked other scientists in our institutes to carefully check English usage. We have redone statistical analysis withMann-Whitney U test. Lung metastases (not survival curve) data were shown in

More details of the animal license and mouse information were added to the Materials and Methods section (page 18). The Author checklist was completed as requested.
Reviewer 3 is also positive and raises one interesting point concerning cyclosporine A (CSA), which was also mentioned by Reviewer 2. Specifically, s/he would like to see further experimentation to establish significance and would like you, ideally, to compare the effect of CSA with ADAP-SAKP55 deficiency. I agree with him/her that this would significantly increase the relevance and impact of your manuscript and therefore encourage you to develop your study in this sense as far as realistically possible. The Abstract could be considerably sharpened. The wording was sometimes ambiguous. For example, in line 5 where it is stated that "KO mice profoundly prevented tumor formation", this needs to be rephrased as something like "knockout of SKAP 55 or ADAP in mice was associated with protection from tumor metastases". In Abstract, line 6: the use of the term "related to" seemed an evasive why to describe a functional relationship.
We have followed the reviewer's suggestion to sharpen and rephrased the sentence the abstract.
The final part of the Abstract re patients who have severe adverse effects against PD-1 mAbs seemed out of step with the actual contents or implications of the study (-possibly an OTT effort to market the work to a translational audience?)
We have deleted this sentence in the abstract.
p3. line 5, typo: "has been shown" Unclear here precisely what the authors mean by the term "clinical anti-tumour activity"
We have rephrased the sentence in the abstract. p3, para 2, line 3. The authors seem to imply that PD-1 effects have been limited to the tumor immunity field, which obviously is not the case
We have rephrased it as "in response to various kinds of antigens such as tumor antigen" (page 3).
p5, para 3, typo " also showed decreased PD-1" p6, para 1, line 2, typo "after being treated"
We have changed to "also decreased PD-1" (page 5) and "after the treatment with"(page 6).
In Figure 1F labeling, the legend and text clarify that this shows over-expression rather than knockout, but this is not clear from looking at labeling of the figure itself. Also, I may have missed this, could not see data on the extent of over-expression after transfection? Figure S1C and S2C).
SKAP55 or ADAP was overexpressed with GFP as fusion proteins. We have checked the expression levels of GFP-SKAP55 or GFP-ADAP by FACS after transfection (supplementary
The point about the phenotype of the knockouts is on the whole well made, but I was disappointed not to see any data from the double knockouts. What phenotype does this give? (Huang et al., 2005; Wang et al., 2007) . The double knockout mice show similar phenotype as ADAP or SKAP55 knockout mice (Fig. 2F, Supplementary Fig. S2D , S3B and S6C). We apologize not providing this information in our previous manuscript, and now have added it in the Discussion (page 15, para 1). p6, para 3, line 13: Would be more clearly rephrased along the lines of " Taken together, this offers the first data in support of....."
We and others previously reported that ADAP KO T cells show a loss of SKAP55 expression
We rewrote the sentence as suggested.
I would have found the tumor protection data more persuasive if some of the information from FigS4B was shown in the main paper and more extensively described. That is, we need to see numbers of metasteses, not just 'survival'. It would also be good to see more comprehensive analysis of T effector infiltrates. Fig. S4B (the survival curve) , and showed numbers of metasteses (Fig. 4A, Fig. S4B .
We have taken the editor and the other reviewer's advice to remove
tumors in lung). Additional analysis including the expression of CD25, CD69, IFN-gamma, Perforin was added in
Referee #2 (Comments on Novelty/Model System):
Referee #2 (Remarks):
We have rewritten the discussion part as suggested (page 15/16).
Specific observations: 1. The manuscript should be carefully revised for the English.
We have carefully revised our manuscript.
2. There is an ethical concern. … The observation of the tumor multiplicity in the lung is an endpoint sufficient to assess the preventive anti-tumor efficacy of the vaccine and is a much more humane endpoint than survival. Survival curves should not be shown.
We thank the reviewer's advice and have removed the survival curve.
3. There is also a major concern about the statistical analysis. Statistical significance was determined with two-tailed Student's t-test, the use of a non-parametric statistical test is strongly recommended.
We have re-done statistical analysis with Mann-Whitney U-test.
4. In the discussion, the authors suggest a new usage of Cyclosporine A for tumour therapy. Nevertheless, in the present study only in vitro studies were done to support this hypothesis and concerns are raised by the fact that Cyclosporine A is a powerful immunosuppressant drug. It would be more appropriate to make this statement more cautious in view of the frequent observation of increased incidence of different types of tumors in individuals treated with cyclosporine.
We have carefully titrated the concentration of CsA that was used to treat WT CTLs in vitro. Then the CsA-treated CTLs were adoptively transferred into the recipient mice that were previously injected with B16 to form tumors under skin. The CsA-treated CTLs could enhance lytic ability to clear tumor effectively in vivo (Fig. 7) .
We (Pyrzynska et al, 2002; Werneck et al, 2012 1) The authors suggest that the ADAP-SKAP55 module should be targeted when/as side effects of anti-PD-1 treatment are severe. Usually this targeting would likely produce a drug which itself may have severe side effects unless the authors think of CSA which, in their assay systems, has a significant effect on PD-1 expression ( figure 3D ). Unfortunately they do not demonstrate statistical significance, although it looks like being significant, and they have not used CSA in their DCvaccine mouse model system. Judging from the in vitro data, it would be interesting to compare the CSA effect with ADAP-SKAP55 deficiency. If the effect would be comparable, as could be expected from the in vitro data, this would be an important notion for the field and their study and CSA could be tested as a "poor man's" anti-PD-1 drug. In this case, the CSA effect should be included into the abstract and the keywords.
We have demonstrated statistical significance in Figure 3D . 2) Without the proper controls (specific/nonspecific competitor probe) an EMSA as in figure 3C is not very meaningful and should be repeated. The indicated band could be nonspecific.
We have included the specific/nonspecific competitor probes as the controls in Figure 3C . Thank you for the submission of your revised manuscript to EMBO Molecular Medicine.
We have now received the enclosed reports from the referees that were asked to re-assess it. As you will see the reviewers are now globally supportive and I am pleased to inform you that we will be able to accept your manuscript pending the following final amendments: 1) Reviewer 3 suggests that you perhaps comment in the discussion that pre-treatment of T cells with CsA before adoptive transfer might be a possible indication. I agree that this would be interesting/useful. 2) Please provide a new supplementary information file without red lettering.
3) We are now encouraging the publication of source data, particularly for electrophoretic gels and blots, with the aim of making primary data more accessible and transparent to the reader. Would you be willing to provide a PDF file per figure that contains the original, uncropped and unprocessed scans of all or at least the key gels used in the manuscript? The PDF files should be labeled with the appropriate figure/panel number, and should have molecular weight markers; further annotation may be useful but is not essential. The PDF files will be published online with the article as supplementary "Source Data" files. If you have any questions regarding this just contact me. 4) Every published paper now includes a 'Synopsis' to further enhance discoverability. Synopses are displayed on the journal webpage and are freely accessible to all readers. They include a short standfirst (to be written by the editor) as well as 2-5 one sentence bullet points that summarise the paper (to be written by the author). Please provide the short list of bullet points that summarise the key NEW findings. The bullet points should be designed to be complementary to the abstract -i.e. not repeat the same text. We encourage inclusion of key acronyms and quantitative information. Please use the passive voice. Please attach these in a separate file or send them by email, we will incorporate them accordingly.
I look forward to reading a new revised version of your manuscript as soon as possible and in any case, within two weeks ***** Reviewer's comments ***** Referee #1 (Comments on Novelty/Model System):
Much sharper now than earlier version Referee #2 (Remarks):
The authors adequately addressed all my criticisms and improved the quality of the manuscript Referee #3 (Comments on Novelty/Model System):
I have read the paper again and I think the authors have made a real efforts to improve the manuscript. They have addressed my comments/criticism adequately. With the additional CsA experiments the whole story is more complete and nicely links the mouse experiments to translational medicine. I am not sure whether physicians will treat their tumor patients with cyclosporine in the future, however, elucidating what the drug is doing is certainly important for the field. On the other hand, pretreatment of T cells with CsA before adoptive transfer to tumor patients may be an indication for CsA and a consequence of their study.
Referee #3 (Remarks):
I have no further comments to the authors. On a last note, however, the authors could mention in the discussion, that pretreatment of T cells with CsA before adoptive transfer to tumor patients could be an indication for this drug.
